Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India
PURPOSEThe COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy.MATERIALS AND...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2021-12-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO.21.00139 |
| _version_ | 1830230405682298880 |
|---|---|
| author | Somnath Roy Joydeep Ghosh Sandip Ganguly Debapriya Mondal Deepak Dabkara Soumyadip Chatterji Bivas Biswas |
| author_facet | Somnath Roy Joydeep Ghosh Sandip Ganguly Debapriya Mondal Deepak Dabkara Soumyadip Chatterji Bivas Biswas |
| author_sort | Somnath Roy |
| collection | DOAJ |
| description | PURPOSEThe COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy.MATERIALS AND METHODSThis is a retrospective study of patients with solid organ malignancies undergoing systemic therapy with a diagnosis of COVID-19 between March 2020 and February 2021. COVID-19 was diagnosed if a reverse transcriptase polymerase chain reaction assay from oropharyngeal or nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2. The objectives were to evaluate the outcome of COVID-19 and factors predicting the outcome.RESULTSA total of 145 patients were included with a median age of 58 years (range, 20-81 years). Treatment was curative in 60 (42%) patients. Of all symptomatic cases (n = 88, 61%), 50 had mild, 27 had moderate and 19 had severe COVID-19–related symptoms as per WHO criteria. Fifty (34%) patients required hospitalization with a median duration of hospital stay of 12 days (range, 4-25 days); five patients required intensive care unit admission. The rest were treated with home isolation and did not require further hospitalization. Twenty-two (15%) patients died, and the risk of death was significantly associated with severity of symptoms (odds ratio, 91.3; 95% CI, 9.1 to 919.5, P = .0001) but not with any other clinical factors. Drug holiday was given to 63 (44%) patients with a median duration of 25 days (range, 7-88 days). The median duration to reverse transcriptase polymerase chain reaction–negative was 16 days (range, 7-62 days).CONCLUSIONCOVD-19–related death rate was 15% among patients with solid organ malignancies. The severity of the symptoms was related to mortality. The majority of patients with mild symptoms were treated at home isolation. |
| first_indexed | 2024-12-18T10:54:06Z |
| format | Article |
| id | doaj.art-f921e22008224d58b1fcb3faba121db7 |
| institution | Directory Open Access Journal |
| issn | 2687-8941 |
| language | English |
| last_indexed | 2024-12-18T10:54:06Z |
| publishDate | 2021-12-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj.art-f921e22008224d58b1fcb3faba121db72022-12-21T21:10:23ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412021-12-0171374137910.1200/GO.21.00139Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern IndiaSomnath Roy0Joydeep Ghosh1Sandip Ganguly2Debapriya Mondal3Deepak Dabkara4Soumyadip Chatterji5Bivas Biswas6Department of Medical Oncology, Tata Medical Center, Kolkata, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, IndiaDepartment of Medical Oncology, Tata Medical Center, Kolkata, IndiaPURPOSEThe COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy.MATERIALS AND METHODSThis is a retrospective study of patients with solid organ malignancies undergoing systemic therapy with a diagnosis of COVID-19 between March 2020 and February 2021. COVID-19 was diagnosed if a reverse transcriptase polymerase chain reaction assay from oropharyngeal or nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2. The objectives were to evaluate the outcome of COVID-19 and factors predicting the outcome.RESULTSA total of 145 patients were included with a median age of 58 years (range, 20-81 years). Treatment was curative in 60 (42%) patients. Of all symptomatic cases (n = 88, 61%), 50 had mild, 27 had moderate and 19 had severe COVID-19–related symptoms as per WHO criteria. Fifty (34%) patients required hospitalization with a median duration of hospital stay of 12 days (range, 4-25 days); five patients required intensive care unit admission. The rest were treated with home isolation and did not require further hospitalization. Twenty-two (15%) patients died, and the risk of death was significantly associated with severity of symptoms (odds ratio, 91.3; 95% CI, 9.1 to 919.5, P = .0001) but not with any other clinical factors. Drug holiday was given to 63 (44%) patients with a median duration of 25 days (range, 7-88 days). The median duration to reverse transcriptase polymerase chain reaction–negative was 16 days (range, 7-62 days).CONCLUSIONCOVD-19–related death rate was 15% among patients with solid organ malignancies. The severity of the symptoms was related to mortality. The majority of patients with mild symptoms were treated at home isolation.https://ascopubs.org/doi/10.1200/GO.21.00139 |
| spellingShingle | Somnath Roy Joydeep Ghosh Sandip Ganguly Debapriya Mondal Deepak Dabkara Soumyadip Chatterji Bivas Biswas Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India JCO Global Oncology |
| title | Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India |
| title_full | Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India |
| title_fullStr | Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India |
| title_full_unstemmed | Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India |
| title_short | Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India |
| title_sort | outcome of covid 19 in solid organ malignancies experience from a tertiary cancer center in eastern india |
| url | https://ascopubs.org/doi/10.1200/GO.21.00139 |
| work_keys_str_mv | AT somnathroy outcomeofcovid19insolidorganmalignanciesexperiencefromatertiarycancercenterineasternindia AT joydeepghosh outcomeofcovid19insolidorganmalignanciesexperiencefromatertiarycancercenterineasternindia AT sandipganguly outcomeofcovid19insolidorganmalignanciesexperiencefromatertiarycancercenterineasternindia AT debapriyamondal outcomeofcovid19insolidorganmalignanciesexperiencefromatertiarycancercenterineasternindia AT deepakdabkara outcomeofcovid19insolidorganmalignanciesexperiencefromatertiarycancercenterineasternindia AT soumyadipchatterji outcomeofcovid19insolidorganmalignanciesexperiencefromatertiarycancercenterineasternindia AT bivasbiswas outcomeofcovid19insolidorganmalignanciesexperiencefromatertiarycancercenterineasternindia |